Back

Formyl-peptide receptor type 2 activation mitigates secondary organ damage in inflammatory arthritis

Margraf, A.; Chen, J.; Christoforou, M.; Claria-Ribas, P.; Henriques Schneider, A.; Cecconello, C.; Bu, W.; Imbert, P. R.; Wright, T. D.; Russo, S.; Blacksell, I. A.; Koenis, D. S.; Dalli, J.; Lupisella, J. A.; Wurz, N. R.; Garcia, R. A.; Cooper, D.; Norling, L. V.; Perretti, M.

2025-02-08 pharmacology and toxicology
10.1101/2025.02.03.636210 bioRxiv
Show abstract

Rheumatoid arthritis (RA) is associated with heart and lung dysfunction. Current therapies fail to attenuate such complications. Here, we identify formyl-peptide receptor type 2 (FPR2) as therapeutic target to treat heart and lung dysfunction associated with inflammatory arthritis. Arthritic mice on high levels of dietary homocysteine develop cardiac diastolic dysfunction and reduced lung compliance, mirroring two comorbidities in RA. Therapeutic administration of a small molecule FPR2 agonist (BMS986235) to hyper-homocysteine arthritic mice prevented diastolic dysfunction (monitored by echocardiography) and restored lung compliance. These tissue-specific effects were secondary to reduced neutrophil infiltration, modulation of fibroblast activation and phenotype (in the heart) and attenuation of monocyte and macrophage numbers (in the lung). A dual FPR1/2 agonist (compound 43) failed to prevent the reduction in lung compliance of arthritic mice and promoted accumulation of inflammatory monocytes and pro-fibrotic macrophages in lung parenchyma. This cellular response lies downstream of FPR1-mediated potentiation of CCL2-dependent monocyte chemotaxis and activation. This finding supports therapeutic development of selective FPR2 agonists to mitigate two impactful comorbidities associated with inflammatory arthritides.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.